| BOIN‐ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes K Takeda, M Taguri, S Morita Pharmaceutical statistics 17 (4), 383-395, 2018 | 83 | 2018 |
| TITE‐BOIN‐ET: time‐to‐event Bayesian optimal interval design to accelerate dose‐finding based on both efficacy and toxicity outcomes K Takeda, S Morita, M Taguri Pharmaceutical statistics 19 (3), 335-349, 2020 | 38 | 2020 |
| The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer S Ozono, T Ueda, S Hoshi, A Yamaguchi, H Maeda, Y Fukuyama, ... Japanese Journal of Clinical Oncology 42 (6), 477-484, 2012 | 37 | 2012 |
| ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in … Y Goto, H Nokihara, H Murakami, T Shimizu, T Seto, AP Krivoshik, ... Journal of Clinical Oncology 33 (15_suppl), 8014-8014, 2015 | 30 | 2015 |
| A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid … N Yamamoto, BY Ryoo, B Keam, M Kudo, CC Lin, F Kunieda, HA Ball, ... Investigational New Drugs 38, 445-456, 2020 | 18 | 2020 |
| gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials K Takeda, S Morita, M Taguri Biometrical Journal 64 (7), 1178-1191, 2022 | 17 | 2022 |
| A simulation study of methods for selecting subgroup‐specific doses in phase 1 trials S Morita, PF Thall, K Takeda Pharmaceutical statistics 16 (2), 143-156, 2017 | 17 | 2017 |
| Clinical activity of ASP 8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations H Murakami, H Nokihara, H Hayashi, T Seto, K Park, K Azuma, CM Tsai, ... Cancer science 109 (9), 2852-2862, 2018 | 15 | 2018 |
| TITE‐gBOIN: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding accounting for toxicity grades K Takeda, Q Xia, S Liu, A Rong Pharmaceutical Statistics 21 (2), 496-506, 2022 | 14 | 2022 |
| A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer H Akaza, H Uemura, T Tsukamoto, S Ozono, O Ogawa, H Sakai, M Oya, ... International Journal of Clinical Oncology 21, 773-782, 2016 | 14 | 2016 |
| Bayesian dose‐finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology K Takeda, K Komatsu, S Morita Pharmaceutical Statistics 17 (6), 725-733, 2018 | 13 | 2018 |
| Bayesian dose‐finding phase I trial design incorporating historical data from a preceding trial K Takeda, S Morita Pharmaceutical statistics 17 (4), 372-382, 2018 | 13 | 2018 |
| Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer H Maeda, K Takeda, H Urushihara, T Kurokawa Cancer Reports 4 (3), e1334, 2021 | 11 | 2021 |
| Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers K Takeda, S Liu, A Rong Statistics in Medicine, 2021 | 11 | 2021 |
| Incorporating historical data in Bayesian phase I trial design: the Caucasian-to-Asian toxicity tolerability problem K Takeda, S Morita Therapeutic Innovation & Regulatory Science 49 (1), 93-99, 2015 | 9 | 2015 |
| Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study Y Yamaguchi, K Takeda, S Yoshida, K Maruo Journal of Biopharmaceutical Statistics 34 (3), 379-393, 2024 | 8 | 2024 |
| TITE‐gBOIN‐ET: Time‐to‐event generalized Bayesian optimal interval design to accelerate dose‐finding accounting for ordinal graded efficacy and toxicity outcomes K Takeda, Y Yamaguchi, M Taguri, S Morita Biometrical Journal 65 (7), 2200265, 2023 | 8 | 2023 |
| Assessment of surrogate end point trends in clinical trials to approve oncology drugs from 2001 to 2020 in Japan H Maeda, R Shingai, K Takeda, A Hara, Y Murai, M Ofuchi JAMA Network Open 6 (4), e238875-e238875, 2023 | 8 | 2023 |
| ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer K Azuma, M Nishio, H Hayashi, K Kiura, M Satouchi, S Sugawara, T Hida, ... Cancer science 109 (8), 2532-2538, 2018 | 8 | 2018 |
| Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN‐ET Y Zhao, R Liu, K Takeda Pharmaceutical Statistics 22 (3), 440-460, 2023 | 7 | 2023 |
